证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 编号：2020-012 | --- | --- | --- | |----------------|--------------------------|--------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | ■现场参观 | | | | □ 其他 | | | 参与单位名称及 | 国泰君安证券 张祝源 | | | 人员姓名 | 富国基金 李淼 | | | | 熙山资本 王威 | | | | 敦和资产 马昀 | | | | 汇利资管 钱希撼 | | | 时间 | 2020 年 12 月 23 | 日 | | 地点 | 实地调研 | | | 接待人员姓名 | | 东诚药业副总经理兼董事会秘书：刘晓杰 | | --- | --- | --- | |-----------------------------|--------- ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 编号：2021-003 | --- | --- | --- | |------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------- ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 编号：2021-004 | --- | --- | --- | --- | |------------------|---------------------------|--------|-------------| | | | | | | 投资者关系活动类 | ■特定对象调研 □分析师会议 | | | | 别 | □媒体采访 | | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | ■其他 （电话会议） | | | | 参与单位名称及人 | 国盛证券 张金洋 | | 祁瑞 | | | 广发证券 | 孔令岩 | 代园炜 | | 员姓名 | 中金公司 | 朱言音 | 陈诗雨 | | | 高瓴资本 | 徐平 | | | | 贝莱德 | 秦瑶函 | | | | 嘉实基金 | 牛歌 | | | | 高毅资产 | 冯鹏 | | | | 德福资本 | 张燕林 | | | | | | | | | 广发基金 | 王瑞冬 | | | | | | | | | 混沌道然 | 蒋晶 | ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 编号：2021-005 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动类 | ■特定对象调研 □分析师会议 | | | 别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | ■其他 （电话会议） | | | 参与单位名称及人 员姓名 | | 广发证券医药分析团队、兴业证 ...

证券代码：002675 证券简称：东诚药业 公告编号：2022-077 烟台东诚药业集团股份有限公司 关于参加山东辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与广大投资者的沟通交流，烟台东诚药业集团股份有限公司 （以下简称"公司"）将于2022年11月16日（星期三）14:00—16:00参加由山东 证监局、山东上市公司协会联合举办并由深圳市全景网络有限公司承办的"山东 辖区上市公司2022年度投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将在深圳市全景网络有限公司提供的网上 平台采取网络远程的方式举行，投资者可以登录全景网"投资者关系互动平 台"(http://ir.p5w.net/）参与本次活动。 届时公司董事长由守谊先生，董事兼总经理罗志刚先生，董事、副总经理兼 董事会秘书刘晓杰先生、财务总监朱春萍女士将通过网络在线交流形式与投资者 就公司治理及社会责任/ESG、经营状况、发展战略、风险防控、投资者保护、三 季度报告等投资者关注的问题进行沟通， ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------|----------------------------------------------------------------| | | | | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | ■其他 （电话会议） | | | 参与单位名称及 | | 平安证券医药团队、西部证券医药团队、方正证券医药团队、广发证 | | 人员姓名 | | 券医药团队、国盛证券医药团队、兴业证券医药团队、民生证券医药 | | | | 团队、德邦证券医药团队、首创证券医药团队、高毅资本、嘉实基金、 | | | | 博时基金、交银施罗德基金、华安基金、 ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 976,379,356.21, representing a year-on-year increase of 0.71%[7] - Net profit attributable to shareholders for Q3 2022 was CNY 161,570,690.08, a significant increase of 51.22% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was CNY 158,711,951.89, up 53.62% year-on-year[7] - Total operating revenue for the third quarter was ¥2,741,441,289.16, a decrease of 1.93% from ¥2,795,453,364.12 in the previous year[36] - Net profit attributable to the parent company reached ¥1,318,298,197.88, up from ¥1,108,320,045.20, representing a growth of approximately 18.9%[35] - The net profit for the current period is CNY 382,790,047.16, an increase of 10.2% compared to CNY 347,477,676.04 in the previous period[38] - The operating profit for the current period is CNY 466,025,637.18, up from CNY 422,277,203.23, reflecting a growth of 10.4%[38] - The total comprehensive income for the current period is CNY 388,130,775.51, compared to CNY 321,585,922.36 in the previous period, indicating a growth of 20.6%[38] Assets and Liabilities - Total assets at the end of Q3 2022 reached CNY 8,502,556,180.25, reflecting an increase of 11.05% from the end of the previous year[7] - Total assets increased to ¥8,502,556,180.25 from ¥7,656,281,227.82, indicating a growth of about 11.06%[35] - Total liabilities rose to ¥2,794,718,408.71, compared to ¥2,632,511,465.23, reflecting an increase of approximately 6.16%[35] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 605,925,147.85, showing a growth of 7.62%[7] - The net cash flow from operating activities is CNY 605,925,147.85, compared to CNY 563,024,536.34 in the previous period, showing an increase of 7.6%[42] - The net cash flow from investing activities is -CNY 346,626,891.73, an improvement from -CNY 440,319,398.93 in the previous period[45] - The net cash flow from financing activities is CNY 173,580,170.66, a significant recovery from -CNY 224,362,727.39 in the previous period[45] - The total cash and cash equivalents at the end of the period amount to CNY 1,179,087,856.76, up from CNY 605,010,867.01 in the previous period[45] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,475[19] - Yantai Dongyi Biological Engineering Co., Ltd. holds 15.57% of shares, totaling 124,888,049 shares, with 60,650,200 shares pledged[19] - The second-largest shareholder, You Shuyi, holds 10.09% of shares, totaling 80,924,299 shares, with 30,500,000 shares pledged[19] - The third-largest shareholder, a private equity investment partnership, holds 5.00% of shares, totaling 40,110,617 shares[19] - The company has disclosed that there are no known relationships or concerted actions among the top ten shareholders[22] Government Support and Investments - The company received government subsidies amounting to CNY 190 million, contributing to cash inflows from financing activities[18] - The company received government subsidies totaling CNY 1 billion in April 2022 and an additional CNY 90 million in July 2022 to support its nuclear medicine industry integration[28] - The company completed the acquisition of a 70.28% stake in Nanjing Yunmi Enterprise Management Partnership for CNY 35.26 million and a 99.90% stake in Nanjing Mi'anbei Enterprise Management Partnership for CNY 114.52 million[28] Research and Development - Research and development expenses increased to ¥99,264,215.39, compared to ¥91,415,634.25, marking an increase of about 8.6%[36] - The company’s subsidiary received approval for clinical trials of a new drug, indicating progress in its research and development efforts[28] Market Expansion - The company plans to raise up to 349.997 million RMB through a private placement of A-shares to supplement working capital and repay interest-bearing debts[23] - The company plans to continue its market expansion and technology integration in the biopharmaceutical sector, supported by local government initiatives[28] - The company announced the operational launch of nuclear medicine pharmacies in Fuzhou, Wuhan, Chongqing, and Kunming throughout 2022, expanding its market presence[28] Miscellaneous - The company reported a tax expense of CNY 81,599,190.50, compared to CNY 74,408,692.80 in the previous period, reflecting an increase of 9.4%[38] - The company received approval from the China Securities Regulatory Commission for a non-public offering of 22,381,379 shares, which will be listed on the Shenzhen Stock Exchange on October 20, 2022[26] - A subsidiary of the company, Hebei Andico Positron Technology Co., Ltd., was recognized as a high-tech enterprise, with the certification valid for three years from December 1, 2021[26] - The company signed a non-binding cooperation letter with ImaginAb, Inc., to become the exclusive distributor for the development, registration, manufacturing, and sales of the product "zirconium Zr 89 crefmirlimaberdoxam" in China[26]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a year-on-year growth of 15%[2] - The company's revenue for the first half of 2022 was approximately ¥1.77 billion, a decrease of 3.33% compared to ¥1.83 billion in the same period last year[27] - The company achieved operating revenue of 1.765 billion yuan, a year-on-year decrease of 3.33%[37] - The company reported a significant increase in revenue, with total sales reaching approximately 1.26 billion CNY, marking a year-on-year growth of 15%[97] - The company's total revenue for the reporting period was ¥1,765,061,932.95, representing a decrease of 3.33% compared to ¥1,825,921,680.64 in the previous year[62] Profitability - Net profit attributable to shareholders increased by 8.89% to approximately ¥168.74 million, up from ¥154.96 million year-on-year[27] - Net profit attributable to shareholders was 169 million yuan, an increase of 8.89% year-on-year, primarily due to improved gross margins in the raw material drug business and exchange rate fluctuations[37] - Basic and diluted earnings per share both rose by 8.85% to ¥0.2103, compared to ¥0.1932 in the same period last year[27] Cash Flow and Assets - The net cash flow from operating activities decreased by 24.30% to approximately ¥345.07 million, compared to ¥455.83 million in the previous year[27] - Cash and cash equivalents at the end of the reporting period amounted to ¥810,449,670.57, accounting for 10.26% of total assets, a decrease of 0.54% from the previous year[70] - Total assets at the end of the reporting period were approximately ¥7.90 billion, an increase of 3.20% from ¥7.66 billion at the end of the previous year[27] - The company's total current assets as of June 30, 2022, amounted to CNY 2,925,866,980.05, an increase from CNY 2,899,768,579.86 at the beginning of the year[194] Market Expansion and Strategy - The company is expanding its market presence, targeting an increase in market share by 5% in the next fiscal year through strategic partnerships and marketing initiatives[2] - The company is actively expanding its market share in the anticoagulant segment, leveraging its raw material advantages and professional marketing teams to enhance brand recognition[55] - The company is expanding its market presence through strategic acquisitions and investments in new projects, enhancing its competitive position[102] Research and Development - The management team emphasizes the importance of innovation and research in driving future growth, with a budget allocation of 100 million RMB for R&D in 2022[2] - The company has established three major R&D technology platforms to accelerate the development of new products and technologies[58] - The company plans to invest heavily in drug research and development, with a focus on developing small molecule compounds for neurodegenerative diseases[99] Risk Management - The company has identified potential risks, including raw material procurement and product quality, and is implementing measures to mitigate these risks[5] - The company is facing risks related to environmental regulations, which may increase operational costs due to stricter compliance requirements[101] - The company has identified a risk of talent shortages as it expands, which may affect its strategic execution and operational efficiency[102] Environmental Compliance - The company has implemented a strict environmental management system, ensuring that pollution control facilities are designed, constructed, and operated simultaneously with main projects[115] - The company has not faced any administrative penalties related to environmental issues during the reporting period[121] - The company has established an online monitoring system for real-time environmental monitoring, ensuring compliance with regulatory requirements[120] Shareholder Information - The company reported a 39.01% investor participation rate in the first temporary shareholders' meeting held on April 29, 2022[106] - The total number of common shareholders at the end of the reporting period was 28,631[171] - The largest shareholder, Yantai Dongyi Biological Engineering Co., Ltd., holds 15.57% of the shares, totaling 124,888,049 shares[176] Acquisitions and Investments - The company made a significant equity investment of ¥114,518,367.00 in Nanjing Mianbei Enterprise Management Partnership, acquiring a 99.90% stake[79] - The company acquired a 70.28% stake in Nanjing Yunmi Enterprise Management Partnership for RMB 35.2625 million and plans to acquire a 99.90% stake in Nanjing Mianbei for RMB 114.5184 million[6] - The establishment of a new company, Mido (Yantai) Biotechnology Co., Ltd., involved a related transaction amounting to RMB 320.1 million[7]

Financial Performance - The company's revenue for Q1 2022 was ¥879,736,270.21, a decrease of 1.18% compared to ¥890,215,161.87 in the same period last year[3] - Net profit attributable to shareholders was ¥54,921,850.86, down 17.90% from ¥66,898,146.52 year-on-year[3] - The net cash flow from operating activities was ¥50,759,287.12, a significant decline of 65.78% compared to ¥148,325,209.80 in the previous year[3] - Total operating revenue for the current period was ¥879,736,270.21, a decrease of 1.5% from ¥890,215,161.87 in the previous period[33] - Net profit for the current period was ¥66,193,178.35, down 25.2% from ¥88,502,966.87 in the previous period[36] - Total profit for the current period was ¥84,781,316.07, down 21.5% from ¥107,959,028.97 in the previous period[36] - Basic earnings per share decreased to ¥0.0685 from ¥0.0834, reflecting a decline of 17.7%[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,815,614,818.26, reflecting a 2.08% increase from ¥7,656,281,227.82 at the end of the previous year[3] - The total liabilities reached CNY 2,730,240,323.97, compared to CNY 2,632,511,465.23 previously, indicating an increase of about 3.7%[29] - The company's equity attributable to shareholders rose to CNY 4,437,625,628.04 from CNY 4,397,415,142.54, marking an increase of approximately 0.9%[29] - The company's current assets totaled CNY 2,917,954,395.26, slightly up from CNY 2,899,768,579.86 at the start of the year[25] - The inventory value increased to CNY 971,580,432.36 from CNY 952,527,907.65, reflecting a growth of approximately 2.2%[25] - The cash and cash equivalents decreased to CNY 726,478,148.84 from CNY 826,611,196.06, a decline of about 12.1%[22] - The accounts receivable increased to CNY 924,230,158.84 from CNY 858,219,453.02, showing a growth of approximately 7.7%[22] Revenue Sources - The company's raw material drug revenue was ¥528,794,100, an increase of 3.74% year-on-year, with gross profit rising by 57.32%[6] - The revenue from the key product, injectable nadroparin calcium, reached ¥98,500,000, marking a 21% increase year-on-year[6] - The company experienced a 38% decline in revenue from Yunk injection, totaling ¥46,430,000, primarily due to the impact of the pandemic on hospital operations[6] Cash Flow and Financing - Cash flow from operating activities generated a net amount of ¥50,759,287.12, down 65.8% from ¥148,325,209.80 in the previous period[40] - Cash inflow from investment activities totaled $194.17 million, down from $239.11 million, indicating a decrease in investment income[43] - Total cash inflow from financing activities was $124.31 million, up from $86.88 million year-over-year, reflecting increased borrowing[43] - Cash outflow for debt repayment was $138.41 million, significantly higher than $94.12 million in the previous period, indicating a focus on reducing debt[43] - The net cash flow from financing activities was -$26.35 million, worsening from -$17.29 million year-over-year, suggesting challenges in financing[43] - The ending cash and cash equivalents balance decreased to $636.29 million from $745.05 million, showing a reduction in liquidity[43] Investments and Subsidiaries - The company plans to raise up to RMB 349.997 million through a private placement of A-shares to supplement working capital and repay interest-bearing debts[15] - The company’s subsidiary, AndiTech, was recognized as a high-tech enterprise, with the certification valid for three years[18] - AndiTech signed a non-binding cooperation agreement with ImaginAb, Inc. to develop and sell licensed products in China[18] - The company received RMB 300 million in government subsidies to support the integration of the nuclear medicine industry in Yantai[18] - A subsidiary received RMB 100 million in government subsidies from the Yantai municipal government[18] - The company’s subsidiary acquired a 70.28% stake in Nanjing Yunmi Enterprise Management Partnership for RMB 35.2625 million[18] - The company plans to acquire a 99.90% stake in Nanjing Mianbei Enterprise Management Partnership for RMB 114.5184 million[18] Research and Development - Research and development expenses rose to ¥37,283,568.45, an increase of 19.5% from ¥31,104,349.40 in the previous period[33] Other Financial Metrics - Other comprehensive income after tax was -¥2,354,776.35, an improvement from -¥3,379,811.02 in the previous period[36] - Cash flow from investment activities included cash received from recovering investments of ¥187,260,000.00, down 21.4% from ¥238,000,000.00 in the previous period[40] - Cash outflow for the acquisition of fixed assets and intangible assets was $83.11 million, up from $61.97 million, reflecting increased capital expenditures[43] - The impact of exchange rate changes on cash and cash equivalents was a positive $3.12 million, compared to $2.96 million previously, indicating some currency gains[43] - The company's first-quarter report was not audited, which may affect the reliability of the financial data presented[44]

Financial Performance - The company reported a total revenue of RMB 802 million for the year 2021, representing a year-on-year increase of 15%[2]. - The net profit attributable to shareholders was RMB 120 million, reflecting a growth of 10% compared to the previous year[2]. - Yantai Dongcheng Biochemicals Co., Ltd. reported a revenue of CNY 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 15%[19]. - The company achieved a net profit of CNY 300 million in 2021, an increase of 20% compared to the previous year[19]. - The company's operating revenue for 2021 was ¥3,912,049,996.56, representing a 14.42% increase compared to ¥3,418,977,548.62 in 2020[31]. - The net profit attributable to shareholders for 2021 was ¥151,561,403.54, a decrease of 63.72% from ¥417,765,795.21 in 2020[31]. - The net cash flow from operating activities increased by 64.80% to ¥943,581,205.86 in 2021, compared to ¥572,576,712.65 in 2020[31]. - The gross margin for the year was reported at 45%, reflecting improved operational efficiency[19]. - The management has provided guidance for 2022, projecting a revenue growth of 12% and a net profit increase of 15%[19]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[2]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[19]. - Future guidance suggests a revenue growth target of 15-20% for 2022, driven by new product launches and market expansion efforts[2]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[2]. - The company is focusing on expanding its anticoagulant product line by accelerating the development of heparin products in compliance with new drug registration regulations[152]. Research and Development - New product development includes a pipeline of 5 innovative drugs expected to enter clinical trials in 2022[2]. - The company has allocated RMB 50 million for research and development in the upcoming fiscal year, aiming for a 30% increase in R&D investment[2]. - Yantai Dongcheng is investing CNY 100 million in R&D for new radiopharmaceuticals, aiming to launch two new products in the next fiscal year[19]. - Research and development expenses increased by 34.10% year-on-year to 168.57 million yuan, with 60.89% allocated to radiopharmaceuticals[90]. - The company is increasing its R&D investment in innovative drugs targeting malignant tumors, neurodegenerative diseases, and cardiovascular diseases, aiming to enhance its research capabilities[152]. Product Development and Innovation - The company has established a new production facility that is expected to increase production capacity by 30% by the end of 2022[19]. - The company has diversified its product line in nuclear medicine, including diagnostic and therapeutic drugs, to meet the growing market demand for precision medical services[76]. - The product line includes key radioactive drugs such as 18F-FDG, with sales revenue of 398.48 million yuan, a 24% increase year-on-year[86]. - The company is developing several key radiopharmaceutical products, including a sodium fluoride injection for bone imaging, which is currently in the final stages of clinical trials[93]. Corporate Governance and Management - The company has maintained compliance with corporate governance regulations, with no unresolved governance issues reported during the year[164][169]. - The board of directors consists of five members, including two independent directors, meeting legal requirements for governance structure[166]. - The company has established a robust internal audit system with a dedicated team of four professionals to oversee daily operations[166]. - The company has not engaged in any significant related party transactions that could compromise its business independence[170]. - The company has a comprehensive salary system based on actual operating performance and performance assessment indicators[196]. Risks and Challenges - The management highlighted risks related to raw material procurement and product quality, which could impact future performance[7]. - The company faces risks related to raw material procurement and price fluctuations, particularly due to the impact of African swine fever on heparin raw material supply[153]. - The company is at risk of performance decline due to increased depreciation from high fixed asset investments, which may not be offset by initial project revenues[153]. - The company acknowledges the potential impact of COVID-19 on its operations, particularly in terms of export orders and domestic sales due to hospital disruptions[157]. Future Outlook - The company plans to leverage its raw material advantages and quality management to expand its market share in the anticoagulant segment[81]. - The company aims to become a "global expert in heparin and a leading enterprise in nuclear medicine in China" by enhancing its product line and production base in nuclear medicine[151]. - The company plans to establish over 30 nuclear medicine pharmacies within three years, covering major cities in China to meet the growing market demand for short half-life drugs[151].